Emerging Trends and Dynamics in the Fungal Eye Infection Market t by 2025

Posted by vinit sawant on April 28th, 2021

Market Highlights

The treatment of fungal infections is limited by lack of innovative therapies due to the low rate of antifungal and antibiotic drug development and costly clinical trials. Thus, the government had changed the regulations and started to support the research & development of antifungal drugs.  

The new regulatory norms have included priority review and regulatory guidance enabling smaller clinical trials. The Generating Antibiotics Incentives Now Act (GAIN Act), by the Food and Drug Administration Safety and Innovation Act, in July 2012 provided incentives, including an extension for the development of new products, fast-track designation, and expedited FDA review for approval.

Global Fungal Eye infection market size is expected to grow at a CAGR of 5.3% during the forecasted period.

Taste the market data and market information presented through more than 115 market data tables and figures spread over 105 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “fungal eye infection market research report–Global forecast till 2023.”

Segmentation

The global fungal eye infection market is segmented on the basis of diagnosis, treatment, and end users.

On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.

Based on the treatment, the market is segmented into antifungal medication, eye surgery, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, research centers, specialty eye clinics, and others.

Key Players

Some of the key players in fungal eye infection market are Allergan Inc., Abbott, Merck & Co., Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Sigma-Aldrich, Novartis AG, Pfizer, Inc., Enzon Pharmaceuticals, Alcon Laboratories Inc., Johnson & Johnson Ltd. and others.